Study to Assess Safety, Tolerability, and Efficacy of GMI-1271 in Patients With Calf-level Deep Venous Thrombosis (DVT)

GlycoMimetics

Status and phase

Terminated

Phase 2

Phase 1

Conditions

Deep Venous Thrombosis

Treatments

Drug: Enoxaparin Sodium (Lovenox®)

Drug: GMI-1271

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT02744833

GMI-1271-220

Details and patient eligibility

About

This study will evaluate the safety profile of GMI-1271 and its effect on thrombus resolution in patients with distal calf vein Deep Venous Thrombosis (DVT).

Enrollment

2 patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Age 18-75 years
Male or female
Diagnosed with acute isolated calf vein Deep Venous Thrombosis (DVT)
Willing and able to participate in all required evaluations and procedures in this study protocol

Exclusion criteria

History or presence of clinically significant medical condition or disease in the opinion of the principal investigator
Uncontrolled acute life-threatening bacterial, viral or fungal infection
Unable to be treated with systemic anticoagulants
Current use of immunosuppressants, antiplatelets (other than aspirin), anticoagulants, and/or anti-epileptics
Diagnosis of acute leukemia or multiple myeloma undergoing active treatment or maintenance treatment within the past 5 years
Current or recent cancer treatment
Major surgery within 21 days or planned surgery during the study period
Female subjects who are pregnant or breastfeeding
Known history of HIV, Hepatitis B or Hepatitis C
Alcoholism or drug use
Clinically significant cardiovascular disease